About EnPlusOne Bio
EnPlusOne Bio is a Healthcare company based in Watertown (United States) founded in 2022 by Daniel Wiegand, Jonathan Rittichier, Daniel Ahlstedt, Howon Lee, and George M Church. Developer of RNA synthesis platform for gene therapeutics. EnPlusOne Bio has raised $46.71 million across 3 funding rounds from investors including Northpond Ventures, Breakout Ventures and Coatue. Its chief executive, as recorded, is Daniel Wiegand. EnPlusOne Bio offers products and services including Solutions. Its focus areas include Life Sciences, Gene Therapy, RNA and Diversified. Its competitors include BridgeBio, Spark Therapeutics and Alnylam; 3 of its 3 listed competitors have raised funding.
Company details
EnPlusOne Bio was founded in 2022 and is based in Watertown, United States. An RNA synthesis platform known as ezRNA is developed by the company within the biotechnology sector. This platform enables enzymatic production of RNA therapeutics incorporating diverse nucleotide modifications. Operations focus on advancing gene therapy applications through scalable synthesis methods.
- Headquarters Watertown, United States
- Founders Daniel Wiegand, Jonathan Rittichier, Daniel Ahlstedt, Howon Lee, George M Church
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website enplusonebio.com
- Social LinkedIn X
- Total Equity Funding$46.71M (USD)
in 3 rounds
- Latest Funding Round$21.82M (USD), Series B
Dec 2024
- InvestorsNorthpond Ventures
& 2 more
Products & Services of EnPlusOne Bio
EnPlusOne Bio offers a comprehensive portfolio of products and services, including Solutions.
Provides enzyme-based innovations for RNA delivery and therapeutics.
Funding Insights of EnPlusOne Bio
EnPlusOne Bio has successfully raised a total of $46.71M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $21.82 million completed in December 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $46.71M
- Total Rounds 3
- Last Round Series B — $21.82M
- First Round $12M
(Sep 2022)
- Investors Count 3
All 3 funding rounds of EnPlusOne Bio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2024 | $21.82M | Series B | – | Northpond Ventures | |
| Apr 2023 | $12.9M | Series A | – | – | – |
| Sep 2022 | $12M | Seed | – | Northpond Ventures |
3 investors in total: 3 institutional.
Investors in EnPlusOne Bio
EnPlusOne Bio has secured backing from 3 investors, including venture fund investors. Prominent investors backing the company include Northpond Ventures, Breakout Ventures and Coatue.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital firm investing in life sciences & tech sectors | npv.vc | Cambridge, United States | ||
Early-stage investments in science-driven companies are made. | breakout.vc | |||
Provider of an investment platform for various stages | coatue.com | New York, United States |
Investor details for EnPlusOne Bio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of EnPlusOne Bio
8 people are tracked at EnPlusOne Bio (5 in leadership, 3 in team).
| Name | Role | Group |
|---|---|---|
Daniel Wiegand | Co-Founder & CEO | Leadership |
Jonathan Rittichier | Co-Founder | Leadership |
Daniel Ahlstedt | Co-Founder | Leadership |
Howon Lee | Co-Founder | Leadership |
George M Church | Co-Founder | Leadership |
Andrew Lee | Board Observer | Team |
Brett Ford | Associate Scientist I | Team |
Dominic R. | Scientist II | Team |
Complete people profiles for EnPlusOne Bio
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of EnPlusOne Bio
3 dated milestones of EnPlusOne Bio across 2 years, from founding to its latest funding, stage changes and deals.
- Founded EnPlusOne Bio is founded.
- Funding First funding round of $12.0M.
- Funding Latest funding round, Series B, of $21.8M.
Competitors of EnPlusOne Bio
EnPlusOne Bio has 3 listed competitors in our database, 3 of them funded. They include BridgeBio, Spark Therapeutics and Alnylam.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | Therapeutics for genetic diseases are developed through targeted interventions. | ||
| sparktx.com | 2013 | Philadelphia, United States | $82.8M | 822 | Gene therapies for rare diseases including retinal dystrophies are developed. | |
| alnylam.com | 2002 | Cambridge, United States | $17M | 2,100 | RNA interference-based therapeutics are developed for multiple disorders. |
Detailed competitors of EnPlusOne Bio
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of EnPlusOne Bio
The website of EnPlusOne Bio (enplusonebio.com) receives about 1.4K visits a month.
- Monthly visits1.4K
▲ 30.3% vs previous month
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as EnPlusOne Bio (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Enplusone Bio
Complete news archive for EnPlusOne Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about EnPlusOne Bio
EnPlusOne Bio was founded in 2022.
EnPlusOne Bio is headquartered in Watertown, United States.
Daniel Wiegand is the CEO of EnPlusOne Bio, as recorded in our data. They have also founded this company.
EnPlusOne Bio is a funded company, having raised a total of $46.71M across 3 funding rounds to date. The company's 1st funding round was a Seed of $12M, raised on Sep 2022.
EnPlusOne Bio was founded in 2022 and is based in Watertown, United States. An RNA synthesis platform known as ezRNA is developed by the company within the biotechnology sector. This platform enables enzymatic production of RNA therapeutics incorporating diverse nucleotide modifications. Operations focus on advancing gene therapy applications through scalable synthesis methods.
EnPlusOne Bio's top competitors include Spark Therapeutics, BridgeBio and Alnylam.
EnPlusOne Bio offers Solutions.
EnPlusOne Bio has 3 investors. Key investors include Northpond Ventures, Breakout Ventures, and Coatue.